Professor Andrew J Pollard
Professor Andrew J Pollard
Verified email at paediatrics.ox.ac.uk
Title
Cited by
Cited by
Year
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10269), 99-111, 2021
25032021
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
The Lancet 396 (10249), 467-478, 2020
16262020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ...
The Lancet 396 (10267), 1979-1993, 2020
8252020
Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant
SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ...
New England Journal of Medicine 384 (20), 1885-1898, 2021
6892021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10277), 881-891, 2021
6012021
Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ...
Cell 184 (9), 2348-2361. e6, 2021
5252021
Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines
AJ Pollard, KP Perrett, PC Beverley
Nature Reviews Immunology 9 (3), 213-220, 2009
4552009
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
OJ Wouters, KC Shadlen, M Salcher-Konrad, AJ Pollard, HJ Larson, ...
The Lancet, 2021
4092021
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease
EF McKinney, PA Lyons, EJ Carr, JL Hollis, DRW Jayne, LC Willcocks, ...
Nature medicine 16 (5), 586-591, 2010
3452010
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization …
N Gossger, MD Snape, LM Yu, A Finn, G Bona, S Esposito, N Principi, ...
Jama 307 (6), 573-582, 2012
3412012
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
The Lancet 397 (10282), 1351-1362, 2021
3402021
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
SH Hodgson, K Mansatta, G Mallett, V Harris, KRW Emary, AJ Pollard
The lancet infectious diseases 21 (2), e26-e35, 2021
3072021
Meningococcal disease: clinical presentation and sequelae
D Pace, AJ Pollard
Vaccine 30, B3-B9, 2012
3042012
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles …
J Findlow, R Borrow, MD Snape, T Dawson, A Holland, TM John, A Evans, ...
Clinical Infectious Diseases 51 (10), 1127-1137, 2010
2972010
Haemophilus influenzae type b conjugate vaccines
DF Kelly, ER Moxon, AJ Pollard
Immunology 113 (2), 163-174, 2004
2832004
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
RC Read, D Baxter, DR Chadwick, SN Faust, A Finn, SB Gordon, ...
The Lancet 384 (9960), 2123-2131, 2014
2632014
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
MD Snape, KP Perrett, KJ Ford, TM John, D Pace, LM Yu, JM Langley, ...
Jama 299 (2), 173-184, 2008
2632008
Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial
ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ...
Jama 315 (15), 1610-1623, 2016
2622016
Emergency management of meningococcal disease
AJ Pollard, J Britto, S Nadel, C DeMunter, P Habibi, M Levin
Archives of disease in childhood 80 (3), 290-296, 1999
2491999
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
K Ewer, T Rampling, N Venkatraman, G Bowyer, D Wright, T Lambe, ...
New England Journal of Medicine 374 (17), 1635-1646, 2016
2472016
The system can't perform the operation now. Try again later.
Articles 1–20